Judgement of the Administrative Court of Cologne: Classification of CBD drops as medicinal products subject to authorization
Standstill in the approval process for CBD products as novel foods
What is new on preliminary injunction proceedings in pharma and biotech cases in Germany – and would it be different under the UPC?
Pharma cases: No proportionality defence without (expedited) request for compulsory license
by Verena Bertram and Dr. Nora E. Wessendorf, LL.M. (Washington)
Update on compulsory licensing in the context of COVID-19 – public consultation of the EU commission
Asserting dependent claims in German patent infringement proceedings
EU Health Technology Assessment (HTA) Regulation (2021/2282) of January 11, 2022.
Background: History of the HTA Regulation
Future gazing with Hannah Kuchler
Three hot IP issues for the pharmaceutical industry
L'UPC avanza; brush up your Italian?
by multiple authors
"State of the art" and trade secret - a contradiction?
Clearing the way by Chinese courts? – Comments on the first NFT copyright infringement decision made by the Hangzhou Internet Court in April 2022